Environmental Protection Agency's ToxCast project is profiling the in vitro bioactivity of chemicals to assess pathway-level and cell-based signatures that correlate with observed in vivo toxicity. We hypothesized that developmental toxicity in guideline animal studies captured in the ToxRefDB database would correlate with cell-based and cell-free in vitro high-throughput screening (HTS) data to reveal meaningful mechanistic relationships and provide models identifying chemicals with the potential to cause developmental toxicity. To test this hypothesis, we built statistical associations based on HTS and in vivo developmental toxicity data from ToxRefDB. Univariate associations were used to filter HTS assays based on statistical correlation with distinct in vivo endpoint. This revealed 423 total associations with distinctly different patterns for rat (301 associations) and rabbit (122 associations) across multiple HTS assay platforms. From these associations, linear discriminant analysis with cross-validation was used to build the models. Species-specific models of predicted developmental toxicity revealed strong balanced accuracy (> 70%) and unique correlations between assay targets such as transforming growth factor beta, retinoic acid receptor, and G-proteincoupled receptor signaling in the rat and inflammatory signals, such as interleukins (IL) (IL1a and IL8) and chemokines (CCL2), in the rabbit. Species-specific toxicity endpoints were associated with one another through common Gene Ontology biological processes, such as cleft palate to urogenital defects through placenta and embryonic development. This work indicates the utility of HTS assays for developing pathway-level models predictive of developmental toxicity.
Environmental Protection Agency's ToxCast project is profiling the in vitro bioactivity of chemicals to assess pathway-level and cell-based signatures that correlate with observed in vivo toxicity. We hypothesized that developmental toxicity in guideline animal studies captured in the ToxRefDB database would correlate with cell-based and cell-free in vitro high-throughput screening (HTS) data to reveal meaningful mechanistic relationships and provide models identifying chemicals with the potential to cause developmental toxicity. To test this hypothesis, we built statistical associations based on HTS and in vivo developmental toxicity data from ToxRefDB. Univariate associations were used to filter HTS assays based on statistical correlation with distinct in vivo endpoint. This revealed 423 total associations with distinctly different patterns for rat (301 associations) and rabbit (122 associations) across multiple HTS assay platforms. From these associations, linear discriminant analysis with cross-validation was used to build the models. Species-specific models of predicted developmental toxicity revealed strong balanced accuracy (> 70%) and unique correlations between assay targets such as transforming growth factor beta, retinoic acid receptor, and G-proteincoupled receptor signaling in the rat and inflammatory signals, such as interleukins (IL) (IL1a and IL8) and chemokines (CCL2), in the rabbit. Species-specific toxicity endpoints were associated with one another through common Gene Ontology biological processes, such as cleft palate to urogenital defects through placenta and embryonic development. This work indicates the utility of HTS assays for developing pathway-level models predictive of developmental toxicity.
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A chemical's capacity to disrupt embryogenesis and cause developmental defects depends on many factors including inherent chemical properties, dose and time of exposure, genetic susceptibility, bioavailability and biotransformation, and chemical interactions with biological systems. Mechanistically, embryonic susceptibility to chemical insult is determined by the sensitivity and specificity with which chemicals (or their metabolites) interact with pathways during particular developmental stages, be it the mother or conceptus. The potential for an adverse outcome is further dependent on the complex cellular and molecular processes governing morphogenesis, growth and differentiation, and the higher-order response (resiliency) of a dynamic system (the developing embryo) to local or systemic perturbations (National Research Council, 2000) .
Given this complexity, the assessment of the potential for chemicals to induce developmental toxicity has largely relied on apical phenotypic endpoint observations from in vivo mammalian studies. For example, the current method for determining a chemical's developmental toxicity potential is outlined in both the U.S. Environmental Protection Agency (EPA) Health Effects Tests Guidelines OPPTS 870 and the Organisation for Economic Co-operation and Development guideline studies, test number 414 (www.oecd-ilibrary.org/environment/oecd-guidelines-for-thetesting-of-chemicals-section-4-health-effects_20745788), which includes a series of rat and/or rabbit prenatal developmental studies. Whereas these tests give an integrated evaluation of developmental toxicity over a broad dose range, they are labor intensive, costly, and require large numbers of test animals. Furthermore, such a high-level assessment does not provide detailed mechanistic information that would inform chemical mode of action (MoA) and facilitate extrapolation and prediction. The sustainability of the traditional testing paradigm has been debated, given the thousands of chemicals in commerce and potentially entering the environment that are lacking adequate developmental toxicity data (Council on Environmental Health, 2011; Hartung, 2010) .
Alternative approaches to traditional developmental toxicity testing in animals have been proposed in the form of in vitro methods and small model organisms, as well as computational toxicology. Many of these approaches use technologies amenable to high-throughput methods, thereby providing a means to screen hundreds to thousands of compounds for a particular biological response (high-throughput screening [HTS] ) or capture information on multiple responses for a particular compound (high-content screening [HCS] ). Alternative methods that aim to predict developmental toxicity have included invertebrate model organisms, such as Drosophila (Schuler et al., 1982) , sea urchin (Hagstrom and Lonning, 1973) , and hydra (Johnson and Gabel, 1983) , as well as vertebrate model organisms such as Frog Embryo Teratogenesis Assay Xenopus, FETAX (Fort et al., 1988) , zebrafish embryos (Birge et al., 1983; Brannen et al., 2010) , and whole mammalian embryo culture (New, 1978; Robinson et al., 2010) . Additional in vitro models include micromass and embryonic stem cell cultures (Chapin and Stedman, 2009; de Jong et al., 2011; Flint and Orton, 1984; Hassell and Horigan, 1982; West et al., 2010) and human embryonic palatal mesenchyme (Welsch et al., 1986) .
EPA's ToxCast and ToxRefDB projects are building a large HTS in vitro data set coupled with a rich in vivo legacy database that provides a novel resource for building predictive models of chemical toxicity, with the initial goal of prioritizing chemicals for further testing (Dix et al., 2007) . The first phase of ToxCast profiled the biological activity of 309 unique chemicals using over 600 HTS/HCS assays including biochemical assays (e.g., nuclear receptor and enzyme activation), cell-based assays (e.g., embryonic stem cell differentiation and cytotoxicity), multicellular complex co-cultures (e.g., inflammatory responses), and small animal models (e.g., zebrafish), as well as chemical property information (actor.epa.gov/actor/faces/ToxCastDB/Home.jsp). For Phase I of ToxCast, many of these chemicals had guideline developmental toxicity in vivo studies entered into ToxRefDB. ToxRefDB contains 30 years worth of acute, chronic, reproductive, and developmental toxicity information on over 400 chemicals (Knudsen et al., 2009; Martin et al., 2009a,b) and is publicly available (actor.epa.gov/toxrefdb/faces/ Home.jsp).
Predictive models have been built using ToxCast in vitro data anchored to ToxRefDB in vivo effects for chronic liver cancer in rodents Shah et al., 2011) and reproductive toxicity in rat multigeneration studies and anchored to biological themes such as pathways important for vasculature development . Here, we hypothesize that predictive models of prenatal developmental toxicity can be derived from the ToxCast in vitro data anchored to the ToxRefDB in vivo studies in pregnant rats and rabbits.
The present study focuses on mining correlations between in vivo developmental defects from ToxRefDB and in vitro profiling from ToxCast. Univariate associations identified by statistical correlations for the ToxCast Phase I chemical library were used to build the species-specific models. The models determined from simple machine learning methods (e.g., linear discriminant algorithms) were statistically robust (balanced accuracy [BA] , which is the average of sensitivity and specificity, > 70%) and differed depending on the species (rat or rabbit) and the specific developmental endpoints/malformations. Annotating assays to Gene Ontology terms (GO biological processes) and mapping these terms to distinct endpoint categories (e.g., cleft palate, renal defects) through univariate associations revealed a systematic network of associations that linked biological processes from in vitro profiling to in vivo activity in prenatal developmental toxicity studies. This novel approach can be used to prioritize chemicals for further testing based on the predicted potential for prenatal developmental toxicity in rats or rabbits.
METHODS
ToxCast Phase I chemical library. Phase I of ToxCast employed a chemical library containing 309 unique structures and some replicates for internal quality control (QC). The rationale for chemical selection was based on several criteria, including available in vivo data from a chronic/cancer, multigenerational/reproductive, or prenatal developmental study (95% of compounds meet these criteria); soluble in dimethyl sulfoxide (97.5% meet this criteria); molecular weight range 250-1000 (90% meet this criteria); and commercially available with purity > 90% (98% meet this criteria). These criteria were largely satisfied with pesticide active ingredients that have had guideline in vivo toxicology studies conducted as part of their registration process with the U.S. EPA. The chemical library spans a wide range of property values and is structurally diverse with over 40 chemical functional classes and over 24 known pesticidal MoA classes. Pesticides were chosen for proof of principle because these chemicals require specific in vivo animal testing. Chemicals were either commercially procured or gathered from internal sources and plated for ToxCast assays by BioFocus DPI (South San Francisco, CA). Certificates of analysis indicated purity > 97% (87% of the chemicals) and > 90% purity for all but a few instances of technical grade or mixtures. Follow-up analysis confirmed mass identification, stability, and purity for over 83% of the chemical library (www.epa.gov/ncct).
Data sources. The data used to link in vivo developmental defects with in vitro chemical profiles are available in ToxCastDB (actor.epa.gov/actor/faces/ ToxCastDB/Home.jsp), which contains information from both the ToxRefDB in vivo guideline studies and ToxCast in vitro assay results. The former (ToxRefDB) contains source data from 1318 prenatal developmental studies mostly in pregnant rats and rabbits from acceptable guideline animal studies (Knudsen et al., 2009) , as well as reproductive and chronic cancer studies (Martin et al., 2009a,b) . The data from the guideline studies have historically been reviewed by regulatory toxicologists and provide the underlying hazard information for risk assessments. ToxRefDB aims to parse these data in a computable publicly available format and is meant to serve as in vivo endpoint anchors in comparing with the ToxCast in vitro data. The ToxCast and ToxRefDB data combined are meant to be used for predictive toxicology research and to support regulatory decision making by providing screening tools, prioritization approaches, and plausible modes of action. All data entered into ToxRefDB have undergone 100% cross-checking for the values entered into the database to ensure systematic QC and underwent an external stakeholder review process (Martin et al., 2009a) . In translating the data from written guideline 110 SIPES ET AL. studies to a computable format, each unique observed endpoint was mapped to a ''category.'' These categories are represented in ToxCastDB as a string of variables: <study type_species_effect_category>, where study type is ''DEV'' if it is a developmental study, species is ''rat'' or ''rabbit'' for the species tested, effect is ''developmental'' or ''maternal'' if the effect is on the mother or fetus, and category is the specific target organ(s) affected. For example, DEV_rabbit_ Developmental_Cardiovascular refers to an observable treatment-related effect on the heart and/or major blood vessels in rabbit fetuses, whether at the dLEL (developmental lowest effect level) or cLEL (categorical lowest effect level). Endpoint categories represented in this data set include fetal weight reduction (FWR), specific malformations and/or anomalies/variations (MAL) (e.g., cleft palate, microphthalmia), and prenatal loss (PNL) (e.g., embryo-fetal death impacting litter size, pregnancy loss, and maternal wastage because separating maternal vs. embryo influences on embryo loss is difficult) ( Table 1) . dLELs are represented for developmental effects including FWR, MAL, and embryo-fetal death impacting litter size. For each endpoint category, data are shown as dosage in milligrams per kilogram per day for the lowest effect level (LEL) on a maternal endpoint (mLEL), dLEL, or cLEL. These definitions of chemicals as potential developmental toxicants are restricted to the purposes of this research study.
ToxCast contains in vitro assay data for 309 environmental chemicals in over 600 HTS assays . The data came from ToxCastDB v17 (November 2010), which is a publicly accessible database with both the in vitro ToxCast and in vivo ToxRefDB data. The data collection for the predictive model was based on 662 HTS assay measurements per chemical from the following platforms: ACEA Biosciences; Attagene, Inc.; Bioseek, Inc.; Cellumen, Inc. (a service brand of Apredica); CellzDirect, Inc. (acquired by Life Technologies); NovaScreen panel (Caliper Life Sciences); NIH Chemical Genomics Center; and EPA's National Health and Environmental Effects Research Laboratory (NHEERL) ( Table 2) . Additional assay definitions and data can be found at: www.epa.gov/ncct/toxcast/data.html (ToxCastAssay-Master_20091214.xls) and actor.epa.gov/actor/faces/ToxCastDB/DataCollec-tionList.jsp. Data are reported as the chemical concentration (micromolar) at half maximal efficacy (AC50) or lowest effective concentration (LEC) for each assay and time-point, as applicable . The complete data set, including AC50/LEC values and corresponding concentration response data for all chemical assay measurement pairs, is available from ToxCastDB (www.epa.gov/ncct/).
Univariate associations for in vivo developmental endpoint categories. To address simple univariate (assay to categorical endpoint) associations, individual ToxRefDB in vivo developmental endpoints were analyzed for their association with individual ToxCast in vitro assays. Each of the 662 in vitro HTS assays was compared with the training set of chemicals, positive and negative for developmental toxicity for any of the 17 categorical endpoints (defined as having any cLEL or not), using continuous (Pearson's correlation test and Student's t-test) and dichotomous (chi-squared test) statistical methodology, with the level of significance returned as p values. The continuous tests compared the distribution of AC50 assay values (potency) between in vivo categorical developmental toxicity (either positive or not) for the chemicals. The dichotomous test used a 2 3 2 contingency table to compare chemicals having positive/negative in vitro assay results (defined as having an AC50 value for a given chemical-assay pair) with in vivo categorical developmental toxicity (either positive or not). In order to pass the initial selection filter for model building, each in vitro assay from the univariate analyses had to have a minimum p value of 0.05 from any method and at least three true positives (chemicals that affected both the in vitro assay and in vivo developmental toxicity).
General rat and rabbit developmental toxicity models. The first step in developing a predictive model of developmental toxicity included selecting those chemicals having evidence for adverse developmental effects in ToxRefDB. As such, the chemical space used for model development focused on a subset of chemical compounds in the ToxCast Phase I chemical library having prenatal rat or rabbit studies in ToxRefDB and availability of in vitro profiling HTS assay data in ToxCastDB. This returned 251 chemicals with rat developmental studies and 234 with rabbit studies. Of those chemicals, the dLEL was used to delineate a positive and negative set for developmental toxicity in either species. Negative chemicals were those tested in a particular species but were not assigned a dLEL due to lack of developmental effects up to the highest dose tested.
Model development followed the same general approach for the predictive model of rodent reproductive toxicity . Here, we built separate predictive models for rat and rabbit developmental toxicity (Fig. 1 ). The first step in the development of the predictive model was univariate assay set selection. Because general developmental toxicity is complex, consisting of a combination of individual in vivo endpoint toxicities, we used the univariate analyses (p 0.05) for the individual in vivo endpoints, from the ''Univariate associations for in vivo developmental endpoint categories'' section, as the initial assay selection filter. The second step in model development was assay set aggregation and reduction. Due to high correlation and observed biological commonality among the filtered in vitro assay set, assays were grouped into individual assay sets based on common gene target, family, pathway, assay platform, or biological function, if there were at least two common assays (a ! 2), and represented as the average of the Àlog 3 (AC50/1000) across each assay to comprise a single assay set. In some instances, assays that did not pass the initial selection filter (i.e., nonsignificant from the univariate analysis) but were complimentary, in terms of common gene target, family, pathway, assay platform, or biological function, to assays that were included in the assay sets were included in the model. These assays included two retinoic acid receptor (RAR) assays for the rat model and two monocyte chemotactic protein-1 (MCP-1) assays and one Note. Developmental defects from ToxRefDB for the 271 chemicals containing information in either rat or rabbit studies are characterized into four categories: dLEL, FWR, MAL, and PNL. dLEL consists of chemicals affecting any developmental endpoint (including FWR, MAL, and embryo-fetal death impacting litter size). FWR consists of fetal weight reduction defects. MAL includes 13 distinct malformation and/or anomaly/variation categories, shown unbolded and include skeletal (axial, appendicular, and cranial), urogenital (renal and ureteric), jaw/hyoid, cleft lip/palate, neurosensory (brain and eye), body wall, splanchnic viscera, and cardiovascular (heart and major vessels) endpoints. PNL consists of embryo-fetal death impacting litter size, pregnancy loss, and maternal wastage.
a This category adjusts for chemical redundancy across the distinct malformation categories. PREDICTIVE MODELING OF DEVELOPMENTAL TOXICITY 111 transforming growth factor beta (TGFb) assay for the rabbit model. The addition of these assays increased overall model performance, i.e., BA. Assays within an assay set were further reduced by descending correlation to the dLEL, and the cutoff for the number of assays within an assay set was chosen where the assay set obtained maximal dLEL association. Using the selected composite assay sets, a multivariate model was developed using linear discriminant analysis (LDA). Fivefold cross-validation (wherein five divisions of the data into 80%/20% chemical sets for training/testing is performed) was used to optimize the model for stability. The resulting cross-validation statistics are presented as the average and standard deviation (SD) of the training and test set balanced accuracies across the five runs.
Data visualization. For cross-species comparison of developmental toxicity models, the predictive models scored and ranked the chemicals based on their activity in the composite in vitro assay set, defined for each species. From the predictive models, each chemical score was the sum across each individual assay set weight factor multiplied by the chemical potency, Àlog 3 (AC50/1000). This model score was used to rank the chemicals, and the rank order was visualized using ToxPi (Toxicological Priority Index) . ToxPi is a flexible prioritization support software tool that incorporates data from HTS assay bioactivity profiles, inferred toxicity pathways, and other sources of information. The ToxPi profiles generated here used the composite assay set for each species model to simply display a visual that represents the relative activity of each model assay set (slice) for the entire chemical set. For each ToxPi, the slice width corresponds with the weight factor for each assay set, and length corresponds with the chemical potency, Àlog 3 (AC50/1000), for that assay set. The larger the weight factor value, the larger the slice width, and the longer the slice, the more potent that chemical is for that assay set. ToxPi was not used to rank the chemicals because the model was built and parameters optimized outside of this framework.
Endpoint-GO biological process map. GO biological processes were compared with the in vivo categorical endpoints using similar univariate association methods to understand the relationship between endpoints and their biological significance. ToxCast HTS assays were mapped to distinct genes where possible, using the assay technical information and the National Center for Biotechnology Information (www.ncbi.nlm.nih.gov), where the mapping from genes to assays can be found in ToxCastDB (actor.epa.gov/actor/faces/ ToxCastDB/Home.jsp). Genes were mapped to GO biological processes if a gene was a component of a particular GO process using the GO annotation system. The AC50 value for a chemical-GO process paring was assigned as the average AC50 value for any gene or protein in that GO process which was affected by a given chemical. Univariate associations between in vivo endpoints (cLEL) and GO biological processes were carried out as described above using a minimum p value of 0.05 from the three test methods mentioned above, positive correlations only, and at least three true positives (chemicals affecting both the endpoint and GO process). These associations were plotted in Cytoscape: An Open Source Platform for Complex Network Analysis and Visualization (www.cytoscape.org) (Cline et al., 2007) . The Cytoscape file for Figure 7 is provided as supplemental data, allowing specific GO biological process annotations to be visualized. Note. Descriptions of assay platforms used in this study including source of the assays, Web site, description, number of assays in ToxCast, and references for the assays used. Additional assay definitions and data can be found at: www.epa.gov/ncct/toxcast/data.html (ToxCastAssayMaster_20091214.xls) and: actor.epa.gov/actor/faces/ToxCastDB/DataCollectionList.jsp 112 SIPES ET AL.
RESULTS

Developmental Toxicity Model Development
To build models for prenatal developmental toxicity, it was first necessary to identify potential developmental toxicants. For the purposes of this research study, potential developmental toxicants were defined as a ToxCast chemical having an in vivo dLEL in ToxRefDB for rat and/or rabbit. We identified 271 ToxCast chemicals containing information in ToxRefDB, with 251 of these tested in pregnant rats, 234 in pregnant rabbits, and 214 tested in both species. A total of 187 unique chemicals were identified as having a dLEL, leaving 60 to be considered negative for developmental toxicity in both species. We did not distinguish a chemical as being ''sensitive'' or ''specific'' for FIG. 1. Predictive model assay selection. ToxCast in vitro HTS assay data consisted of AC50 values for 309 chemicals 3 662 assays. ToxRefDB in vivo prenatal developmental toxicity test endpoints were organized into 17 categories, yielding cLELs for 251 chemicals in the rat and 234 chemicals in the rabbit. ToxCast and ToxRefDB data were compared via univariate analyses, assay sets were aggregated and reduced, and the composite assay set was run through LDA for model assessment as described in the ''Methods'' section. The variables g, r, and s represent a given gene, group, or single assay, where G, R, and S represent the total number of genes, groups, or single assays, respectively. PREDICTIVE MODELING OF DEVELOPMENTAL TOXICITY adverse pregnancy outcomes for this modeling effort. By sensitive, we mean developmental effects recorded in ToxRefDB at or below maternal toxicity dose levels, and by specific, we mean a dLEL without maternal toxicity (no mLEL) (Knudsen et al., 2009 ). Of the chemicals tested in each species and recorded in ToxRefDB as having a dLEL, 146 were positive in the rat (58%) and 106 were positive in the rabbit (45%), with 65 overlapping chemicals (Table 1) . This moderate chemical overlap space, along with the historic differences in chemical toxicity seen in rats and rabbits, supported the decision to develop species-specific models of developmental toxicity.
We evaluated correlations between in vivo dLEL or mLEL and the number of in vitro assays that were positive (indicated by an AC50 value) for each chemical. We plotted the relationship between in vivo developmental activity (Àlog 3 ((dose in mg/kg/ day)/10,000)) and promiscuity (number of assays positive across 662 assays) for rat or rabbit endpoints. Initial analysis revealed no simple relationship between in vitro promiscuity and in vivo developmental activity; that is, the developmental toxicity potential of a ToxRefDB chemical could not be inferred simply from the generic number of assays perturbed in ToxCast (Fig. 2) . Neither was a simple trend evident when the data were parsed by mLEL. For that reason, we considered all chemicals in the predictive model, regardless of whether they affected no assays, a few specific assays or multiple diverse assays. For example, specific activity on a narrow but relevant developmental pathway (e.g., TGFb) could be highly relevant to a predictive model and so all chemicals were considered for model building purposes. Chemical solubility (e.g., logP), instability, or biotransformation issues were not considered in this modeling effort, although we acknowledge that including such information could potentially strengthen the model performance.
Univariate Associations for In Vivo Developmental Endpoint Categories
We sought to determine the associations between the specific in vivo endpoint categories and the assays as a first step toward a global predictive model of developmental toxicity. Chemicals with a dLEL can affect a variety of endpoints in ToxRefDB, including FWR, MAL, and embryo loss, with potentially very different mechanisms of disruption. Table 1 gives the number of chemicals across endpoint distribution. There were 187 unique chemicals with a dLEL recorded in ToxRefDB and 44 with a maternal-related PNL but no dLEL. There exists redundancy across endpoints due to the fact that a particular chemical may have been reported to cause one or many defects at the dLEL. The chemical space overlapped between both species at most by 60% for a given species in all four broad categories (dLEL, FWR, MAL, and PNL), and the only MAL subcategory to exhibit overlap was the skeletal system.
Univariate associations were evaluated to find biologically meaningful relationships between specific in vivo categorical endpoints and cellular targets of the in vitro HTS assays. Univariate associations based on the 16 cLEL ToxRefDB categories (not including the broad MAL category) for rat and rabbit developmental outcomes were classified by endpointtarget contingency tables. Although there was no trend for a chemical's developmental or maternal toxicity and number of assays affected between species (Fig. 2) , the nature of developmental defects varied considerably between species (Table 1) . This implies that the univariate associations would vary between species as well. Overall, this analysis returned 423 univariate associations. Univariate associations showed a nonuniform distribution across the 17 endpoint categories assessed here (Table 3) . Most (301 total) were rat dependent, but 122 were rabbit dependent with MAL having the most associations in either species. For disaggregated (categorical) endpoints, most univariate associations were correlated with FWR, PNL, urogenital, cleft palate, and skeletal defects in the rat and FWR, PNL, and skeletal endpoints in the rabbit (Table 3) . As such, the number of univariate associations did not reflect the number of chemical-endpoint effects, potentially indicating that chemicals affecting a single endpoint category may be affecting similar assays and/or pathways or may be affecting very different assay sets and/or pathways. For example, 15 chemicals had a cLEL for renal defects in the rat versus 113 chemicals for axial skeleton defects (Table 1) , whereas the univariate associations numbered 60 and 29, respectively, for these systems (Table 3) .
FIG. 2. Lack of correlative relationship between in vivo toxicity and number of assays affected. Chemicals tested in ToxRefDB for rat and rabbits were plotted by their developmental (dLEL) and maternal (mLEL) toxicity potential (Àlog 3 ((dose in mg/kg/day)/10,000)) (A) for rat and (B) rabbit species. Chemicals are ordered hitting the least number of assays in the ToxCast screening to the most number of assays (left to right). Number of assays hit by the chemical is listed on the x-axis. 114 SIPES ET AL.
Species differences in the malformation categorical endpoints show that most rat associations correspond to urogenital, skeletal (axial and appendicular), and cleft lip/palate (CLP) categories, whereas rabbit associations correspond to skeletal (axial, appendicular, and cranial) categories (Table 3) . Very few assay associations overlap between the species. This may be indicative of different targets being perturbed, chemicals affecting different endpoints potentially because of differences in rates of embryogenesis and maternal and placental physiologies, dose level and extent of exposure at the target site, or the inherent nuances due to study designs over the years (e.g., exposure window, strain differences in gestational age, how time-to-pregnancy is measured, and length of gestational exposed in rat and rabbit). There were, however, four common in vitro HTS assay targets for the rat and rabbit dLEL categories, namely cytochrome P450 enzymes CYP2A2 and CYP1A1, tumor necrosis factor alpha (TNFa), and prostaglandin e2 (PGE2). The CYP and PGE2 assays were included in both species' developmental toxicity models. There were 12 common associations for the aggregated MAL endpoint. The predominant endpoints from these common associations were skeletal defects and neurosensory defects in the rabbit studies and skeletal and urogenital endpoints in the rat (data not shown). The stratification of univariate associations by technology platform is shown in Figure 3 .
We next examined univariate associations with respect to in vitro HTS assay targets. Assay targets versus in vivo developmental defects for rabbit and rat were plotted as shown in Figure 4 . Individual assay targets are shown along with their categorized functional groups, such as chemokine signal, Gprotein-coupled receptor (GPCR), kinase/phosphatase activities, tissue factor, xenobiotic-intermediary metabolism, nuclear receptor, nuclear factor, channel transporter, murine embryonic stem cell (MESC), and cellular morphological assays. The heatmap on the right side of each panel reflects the total number of associations for a particular cellular target over the various developmental endpoints. Although there are more rat associations (331) than rabbit (141), the heatmap shows distinct trends between species in this data set.
Species differences. Species differences were evident among statistically correlated target groups from the HTS in vitro assays with in vivo categorical endpoints (Fig. 4) . Endpoints with the most correlations include FWR, urogenital (renal and ureteric) defects, CLP, skeletal (appendicular and axial), and fetal loss in the rat and FWR, skeletal axial, and PNL in the rabbit. Most rabbit associations were connected to tissue factor (3-48 true positives [TPs]) and chemokine signal groups (3-38 TPs), whereas most rat associations were connected to xenobiotic-intermediary metabolism (3-102 TPs) and kinase/phosphatase groups (mostly 3 TPs). Univariate associations were distinct for each species. In the rat, xenobiotic-intermediary metabolism, channel-transporters, and cell-based assays correlated mostly with urogenital defects and cleft palate, whereas these assays minimally correlated with rabbit defects. Additionally, a subset of chemokine signal, GPCR, metabolism, and nuclear factor groups associated with rabbit axial skeletal defects while minimally correlating with rat defects.
Intra-species differences. Intra-species differences are seen for the various developmental outcomes. Although the kinase/ phosphatase targets associate mainly with FWR and PNL in the rats, this is due to three chemicals (maneb, mancozeb, and metiram zinc). Cell-based assays associated mainly with rat renal (5-12 TPs) endpoints. Additionally, urogenital and skeletal axial endpoints correlated exclusively with mitochondrial disruption assays. The urogenital categorical endpoint exclusively affected MESC down assays, whereas an increase in MESC cell number was associated with PNL. Examples for the rabbit associations reveal similar trends of specific targets associating with specific endpoints. Roughly half of the tissue factor targets associate with DEV defects, whereas 25% exclusively associates with PNL. Note. Developmental defects from ToxRefDB for the 271 chemicals containing information in either rat or rabbit studies are characterized into four categories: dLEL, FWR, MAL, and PNL. dLEL consists of univariate associations linked to any developmental endpoint (including FWR, MAL, and embryo-fetal death impacting litter size). FWR consists of fetal weight reduction defects. MAL includes 13 distinct malformation and/or anomaly/variation categories, shown unbolded and include skeletal (axial, appendicular, and cranial), urogenital (renal and ureteric), jaw/hyoid, cleft lip/palate, neurosensory (brain and eye), body wall, splanchnic viscera, and cardiovascular (heart and major vessels) endpoints. PNL consists of embryo-fetal death impacting litter size, pregnancy loss, and maternal wastage. Sensitivity and specificity evaluation of univariate associations. To assess the statistical relevance of the univariate associations, each in vitro assay association was plotted as the TP rate (sensitivity) against the false-positive (FP) rate (1specificity). This was done to map the various in vitro targetin vivo endpoint associations as inputs for machine learning. Strictly mapping individual univariate points assumes those furthest from the diagonal (random) have greater diagnostic value. Sensitivity analysis was evaluated for each endpoint (Fig. 5) . dLEL associations produced a weak predictive trend only slightly improved over random (Fig. 5A ). This was also the case for FWR ( Fig. 5B ) and PNL (Fig. 5C ). Diagnostic value increased substantially when the sensitivity analysis considered specific developmental defects. Most likely, this is because a chemical will be affecting fewer pathways for disrupting each specific malformation than for causing a dLEL, FWR, or PNL. For example, chemical effects on several assays showed moderate sensitivity and specificity for rat CLP and ureteric defects (Fig. 5D ). Rabbit jaw/hyoid, neurosensory (eye and brain), and splanchnic viscera endpoints were more sensitive than specific (Fig. 5E ).
Rat Developmental Toxicity Model
Twelve assay sets were identified in building the model for rat developmental toxicity of which eight were considered positive predictors and four were negative predictors (Table 4) . Positive predictors are assay sets that were positively correlated with developmental toxicity (i.e., chemicals having a dLEL in general affected these assays, whereas chemicals tested in a species but without a dLEL did not). Negative predictors are assay sets that were negatively correlated with developmental toxicity (i.e., chemicals tested in a species but did not have a dLEL generally affected these endpoints, whereas chemicals having a dLEL did not), which may indicate a protective mechanism. The following 12 assay sets were stratified based on their weight factor: (1) RAR included two transcriptional assays and one receptor-binding assay; (2) GPCR included the purinergic (PY2), opiate (opiate_mu), opiate receptor-like 1 (ORL1), and the muscarinic cholinergic rececptor 1 (M1) GPCR-binding assays, which were among the highest correlating GPCRs; (3) TGFb included protein expression and transcription factor binding activity assays; (4) MT (microtubule destabilization) imaging assay; (5) SENS_CYP (cytochrome P450) included two CYP transcription factor binding activity assays (CYP1A1 and CYP2B6) affected by at least 88 chemicals; (6) AP1 (activator protein 1) transcription factor binding activity assay; (7) SLCO1B1 (solute carrier organic anion transporter family member 1B1) expression assay; (8) CYP enzyme assays (CYP2A2 and CYP2B1) affected by a maximum of 27 chemicals; (9) HLA-DR (major histocompatibility complex) as a negative predictor included an increase in protein expression; (10) PXR (pregnane X receptor) expression assay was also a negative predictor; (11) interleukin (IL)8 was a negative predictor including two assays showing decreases in protein expression; and (12) PGE2 (prostaglandin receptor) as a negative predictor included decreases in protein expression. These assay sets reflect a number of target pathways relevant to developmental processes and toxicities. show more associations for rat than rabbit endpoints (dLEL, FWR, MAL, and PNL) over the ToxCast assays (pmin 0.05, TP ! 3). Numbers in parentheses indicate total number of assays in each platform. Associations aggregated by species revealed more rat-associated assays for all platforms with the most contributions from the absorption, distribution, metabolism, and excretion (ADME) and enzyme (ENZ) NovaScreen (NVS) assays. (B) Specific endpoint univariate associations show broad associations with ToxCast assays with the most to least being MAL (malformations and/or anomalies/variations), PNL (prenatal loss), and FWR. Note the MAL category consists of multiple univariates from individual endpoints. Assays stratified over aggregated endpoints (FWR, MAL, and PNL) generally revealed more MAL associations for each platform with the most contributions from the ADME and ENZ NVS assays and the BSK inflammatory response assays. Overall, the BSK platform gave more associations as well as the biochemical HTS platform (NVS). ACEA, ACEA Biosciences; NCGC, NIH Chemical Genomics; CLM, Cellumen (Apredica); ATG, Attagene; CLZD, CellzDirect; NVS_OTHER, NovaScreen other assays; NVS_NR, NovaScreen nuclear receptor assays; NVS_GPCR, NovaScreen G-protein-coupled receptor assays; NVS_ADME, NovaScreen CYP assays; NVS_ENZ, NovaScreen enzyme assays; BSK, Bioseek. Different weighting factors were assigned to the 12 assay sets using LDA to optimize the BA in the model (Table 4 ). The weighting factors define overall contribution of each assay set to the model. The highest weighting factors were assigned to the RAR and GPCR assay sets, mainly due to high specificity for a subset of chemicals with a dLEL. The SENS_CYP assay set improved the model sensitivity (affected by 209 chemicals). The negative predictors PXR, IL8, and PGE2 were sensitive assay sets (affected by ! 54 chemicals) that helped to minimize FPs. The remaining assay sets were affected by a minimal number of chemicals ( 18 chemicals for MT, SLOC1B1, and HLA-DR) or by a moderate range (! 39 chemicals for RAR, TGFb, and CYP). These assay sets had different weighting factors and significance values associated with the dLELs, but all assay sets helped to maintain overall model BA.
Modeling the data using the 12 assay sets yielded a training BA of 71% (± 1% SD) with a p value of 7.5 3 10 À11 (Table 5 ). In order to achieve the 71% training BA, a model score cutoff value was given from the LDA analysis. The sensitivity and specificity was 72 and 70%, respectively. When subjected to fivefold cross-validation within the data set, this model returned a test BA of 70% (± 9% SD). These results are reasonable for a preliminary model, given there was no a priori filtering applied.
Rabbit Developmental Toxicity Model
Seven assay sets were identified in building the model for rabbit developmental toxicity of which five were considered positive predictors and two were considered negative predictors ( Table 6 ). The assay sets are stratified based on their weight factor: (1) CCL2 (chemokine ligand 2) (MCP1, monocyte (by ToxRefDB malformation data) in the order of increasing severity from FWR to MAL to PNL, shown by increasing color intensity. Univariate associations are represented by colored boxes where empty boxes are no associations. Color-ribbon values are the total number of univariate associations across in vitro assay targets (vertical) and endpoint categories (horizontal) visualized by increasing number of univariate associations (yellow to red). *Indicates multiple potential targets. chemotactic protein 1) included five small cytokine protein expression assays; (2) IL included protein expression assays of IL1a and IL8; (3) CYP included a CYP1A1 expression and CYP2A2 enzyme inhibition assay, as in the rat developmental toxicity model; (4) TGFb included two protein expression assays, much like the rat developmental toxicity model, but with only one specific assay in common; (5) MESC included assays measuring a decrease in cell number and MHC (myosin heavy chain) expression; (6) SULT2A1 (sulfotransferase) expression assay as a negative predictor; and (7) PGE2 (prostaglandin receptor) as a negative predictor similar to the rat model. Different weighting factors were assigned to the seven assay sets using LDA to optimize the BA in the model ( Table 6 ). All of the assays were moderately sensitive (affected ! 47 chemicals), but the highest weighting factors were assigned to the CCL2 and IL assay sets, which were more specific than the CYP, TGFb, and MESC assay sets. The negative predictor SULT2A1 was the most specific as determined by the ratio of the number of chemicals that had a dLEL and affected the assay (true positive) over the number of chemicals that did not have a dLEL and did not affect the assay (true negative). PGE2 was the least specific but helped to decrease the score of FPs. These assay sets were all significantly associated with the dLELs (p values were 0.1).
Modeling the data using the seven assay sets yielded a training BA of 75% (± 2% SD) with a p value of 7.2 3 10 À13 (Table 7) . The sensitivity and specificity were 70 and 78%, respectively. When this model was subjected to fivefold cross-validation within the data set yielded a test BA of 71% (± 3% SD). These results are reasonable for a preliminary model, given there was no a priori filtering applied.
ToxPi Profiling and Concordance
The Phase I chemical library data set was run through each species model for ranking, and these rankings were then visualized as ToxPi (Fig. 6) . The model score for each Note. Individual assays are listed along with the weighting factor, correlation, and p value with respect to the rat dLEL for each assay set.
PREDICTIVE MODELING OF DEVELOPMENTAL TOXICITY 119 chemical was based on the in vitro activity profile from the HTS assays of the selected composite assay set for each model. Higher scoring chemicals are predicted to be more likely developmentally toxic than chemicals with lower ranking scores. The top left ToxPi is the chemical predicted to most likely be a developmental toxicant for the given species, whereas the bottom most ToxPi is the least likely. Optimizing the model through LDA gave the cutoff values for developmental toxicity in species-specific models, which are shown as black bars in the figures (Fig. 6 ). Red-yellow and blue slices of ToxPi indicate positive and negative assay set predictors, respectively. Chemicals with the highest activity among positive and negative predictors are ranked highest and lowest, respectively. Chemicals in the middle either have little activity for the given assay sets or had near equal activity in both positive and negative predictors. For predicted rat developmental toxicants, a combination of assay sets were evident for the highest ranking chemicals, although a number of chemicals only affected a single positive predictor, such as TGFb and SENS_CYP (Fig. 6A ). For predicted rabbit developmental toxicants, a combination of assay sets were evident for the highest ranking chemicals, with most containing a CCL2 assay set, although a number of chemicals only affected a single positive predictor, such as CCL2, IL, CYP, and TGFb (Fig. 6B ). Low-ranking chemicals for speciesspecific models showed little bioactivity across the HTS assays and the least ranking chemicals primarily affected negative predictors. Next, we examined concordance between the speciesspecific models (Table 8) . Each model was analyzed independently over the collective 309 ToxCast chemicals using model cutoff values preset as described above (see Tables 4, 5 , 6 and 7). Whereas the primary species model gave ! 71% BA in each case, the secondary species gave BA of 62% (rat to rabbit) and 53% (rabbit to rat) for dLEL predictivity. As such, both models contribute unique species-specific information in predicting developmental toxicity.
Endpoints Linked through GO Process Associations
Univariate associations of GO biological processes (www.geneontology.org) were plotted in Cytoscape ( Fig. 7 ; Supplemental data; www.cytoscape.org). This map has the potential to show meaningful relationships between cellular Note. Individual assays are listed along with the weighting factor, correlation, and p value for each assay set. processes and in vivo endpoints and how the endpoints are associated with each other through these processes. Most endpoints shared at least one biological process with another endpoint, except for rabbit splanchnic visceral defects. A hub of GO processes (lymph node, salivary gland, and muscle development, germ cell migration, TGFb signaling, proliferation, differentiation, ossification, and collagen regulation) connect a number of endpoints including, rat FWR, dLEL, axial skeleton, body wall, cleft palate, and rabbit FWR. Rat FWR also clusters with rat CLP, appendicular, cranial, and PNL. Rabbit FWR appears to connect to a number of endpoints but with only one or two associations. Rat urogenital endpoints cluster together with rat CLP (via placental and embryonic development, aging, growth, NF-jB, response to drug, and apoptosis). Common GO process themes include migration, inflammatory signaling, blood vessel development, and proliferation.
DISCUSSION
Predictive modeling of potential in vivo developmental toxicity from in vitro data is a complex problem that is confounded by many factors such as chemical perturbations of key developmental pathways, intracellular and tissue-level crosstalk, xenobiotic metabolism, and chemical solubility and partitioning. This study is the first attempt to construct predictive models of developmental toxicity based on broad spectrum profiling of biological activity in HTS assays. Results of this study demonstrate the following findings: (1) individual species-specific models are necessary for predicting developmental toxicity in pregnant rats and rabbits, (2) plausible cellular targets and pathways can be linked to specific endpoint toxicity, (3) toxicity endpoints cluster together based on similar biological process associations indicating potential similarities in developmental stage or processes, (4) xenobiotic metabolism plays a role in developmental toxicity, (5) there is no clear trend between in vivo chemical dose and assay characteristics, and (6) this analysis demonstrates the capability of using HTS assays to predict developmental toxicity. Taken together, these data indicate for the first time that ToxCast HTS of a large number of compounds can produce in vitro bioactivity profiles that can predict, with a BA of over 70%, in vivo developmental toxicity potential.
Species Specificity
Mammalian species, genotype, and gender have been known to be factors associated with a chemical's potential to cause developmental toxicity. The weak concordance between rat and rabbit predictors could reflect the Phase I chemical space, the assay sets used for model building, the predictivity of speciesspecific models, or that univariate associations minimally overlap between species. These data do not indicate which species might be more or less relevant for human developmental toxicity but suggest that there is a pronounced separation in developmental toxicity between both species, seen from both the chemical and assay space. This is especially noteworthy considering the majority of in vitro assay targets were human genes/cells/proteins, yet the human-based predictive models still yielded a clear delineation between rats and rabbits.
Compounds without an acceptable in vivo guideline study but among the top 22 chemicals predicted to be most likely developmental toxicants using species-specific models ( Fig. 6 ) have literature documentation of developmental toxicity. Imazalil made the top 22 for both species and along with other imidazoles have been indicated in rat whole embryo culture and zebrafish toxicity (Menegola et al., 2006; Sisman and Turkez, 2010) . Specifically, for the rat model, PFOS has been shown to affect mammalian survival and hypothyroxinemia (Lau et al., 2003; Luebker et al., 2005) and MEHP administration in mice showed teratogenicity (Yagi et al., 1980) . For the rabbit model, malaoxon has been shown to cause chick teratogenicity (Walker, 1971) ; however, prometon has not been shown to be embryotoxic. Additionally, depending on the intended application, cutoff values set from LDA analysis may be increased to reduce the number of compounds considered positive for developmental toxicity thereby generally increasing specificity or decreased to increase the number of positives thereby generally increasing sensitivity for either species to tailor the models for specific applications. Such an approach may further help to prioritize targets and pathways for gaining a better understanding of mechanisms. Note. Species-specific models including the optimum cutoff values were used to evaluate the predictivity of developmental toxicity in the other species. These data indicate that species-specific models can only accurately predict (BA > 70%) species-specific developmental toxicity for which the model was built. Acc, accuracy; FN, false negative; NTN, not tested (and predicted to be) negative; NTP, not tested (and predicted to be) positive; Sens, sensitivity; Spec, specificity; TN, true negative. 122 SIPES ET AL.
Mechanistic Implications
The predictive models reveal biologically plausible linkages to molecular targets and processes and possible modes of action for developmental toxicity. ToxRefDB contains in vivo data from many different rat strains, and the ToxCast HTS assays consist of data collected on a variety of human and rat cell lines, mouse primary cells, and proteins and genes from a variety of species assayed in cell-free formats. Even with this diversity (genetic and technical), the predictive models may reflect groups of genes and proteins that work together in cellular processes fundamental to embryogenesis and pregnancy-regardless of species, genotype, or gender. For example, the CYPs, TGFb, and PGE2 were represented in both species models of developmental toxicity. CYPs are important enzymes in drug and steroid metabolism (Finnell et al., 1995; Hines, 2008) , TGFb signaling is critical for morphogenesis and differentiation, and PGE2 plays a role in the pregnant uterus (Lim and Dey, 1997; Wanggren et al., 2006) . These may give an indication into which pathways represent common routes between species for chemical effects on development.
Species-specific targets also have known roles in prenatal development. The rat model included the purinergic, opioid, and muscarinic acetylcholine GPCRs, which play a role in brain development (Lauder and Schambra, 1999; Majumder et al., 2007; Vernadakis et al., 1990) , and CYPs and microtubules have roles in metabolism and preimplantation, respectively (Davis et al., 2010; Maro and Pickering, 1984) . RAR, TGFb, and AP-1 have established roles in development (Jochum et al., 2001; Mark et al., 2009; Wu and Hill, 2009) . The negative predictor PXR may indicate a metabolic factor for drug toxicity indicating a protective mechanism or may be a side effect of being affected by a number of chemicals. Human leukocyte antigens (HLA) and ILs are involved in the inflammatory signaling cascade and trophoblast migration (Jovanović et al., 2010; von Rango, 2008) . On the other hand, some targets, such as SLCO1B1 (solute carrier organic anion transporter family member 1B1), had no established role in developmental toxicity; however, other transporters such as ABCB1 and ABCG2, which had univariate associations with rat developmental endpoints, play roles in chemical susceptibility to birth defects and stem cell plasticity (Chandler et al., FIG. 7 . Univariate associations clustering in vivo endpoints based on HTS GO biological processes. GO biological processes were linked to ToxCast assays through genes and further to endpoints through univariate analysis (pmin 0.05, TP ! 3, correlation > 0). Endpoint to GO process univariate analyses were plotted in Cytoscape using the spring embedded clustering method. Terms listed indicate cellular targets or processes enriched in the circled GO processes. PREDICTIVE MODELING OF DEVELOPMENTAL TOXICITY 2011; Ding et al., 2010; Lankas et al., 1998) . The rabbit model-specific assay sets include CCL2, which is correlated with early detection of pregnancy and has been suggested to be a marker of toxemia, an accumulation of toxic metabolites that may lead to an imbalance in energy between the maternal-fetal unit (Boomsma et al., 2009; Yarim et al., 2007) . CCL2 has also been indicated as a potential marker for disruption of vascular development . Interestingly, the stem cell differentiation and cytotoxicity correlated with rabbit developmental toxicity and have been shown to predict developmental toxicity (Chapin and Stedman, 2009; West et al., 2010) . Finally, the sulfotransferase acts upon many factors including steroids, alcohol, drugs, and xenobiotic compounds, which like PXR, may indicate a protective mechanism. The evidence that these targets have important roles in developmental toxicity gives plausibility to these assay sets for predicting developmental toxicity.
Endpoint Clustering through Biological Processes
Susceptibility of an organ to chemical perturbations is dependent on the genotype and developmental stage at which an embryo might be exposed either directly or indirectly through a maternal effect (Daston and Manson, 1995) . Critical periods of development have been identified for various organ systems and the corresponding windows of greatest vulnerability. It is expected that some developmental defects would cluster together, based on overlapping windows of vulnerability during organogenesis. For example, rat cleft palate and urogenital defects are among the last organs to complete organogenesis. We see a similar trend in the data where cleft palate and urogenital defects are clustering together around assay targets and common GO processes. The assay targets from the univariate associations include CYP activation/inhibition, ATP-binding cassette transporters (ABCG2 and ABCB1) inhibition, increase in prostaglandin protein expression (PTGER2), androgen receptor binding (AR), tumor necrosis factor receptor activation (TNFRSF10B), and stress activation (JUN/AP1). The conazole fungicides were highly represented in these endpoints with flusilazole and propiconazole affecting both endpoints, cyproconazole specifically affecting cleft palate, and diniconazole, tetraconazole, paclobutrazol, and triadimenol affecting urogenital defects. These conazoles were among the highest scoring for both developmental toxicity models (Fig. 6 ). As mentioned above, the ATP transporters have been linked with embryonic stem cell pluripotency, which is most likely the link to the embryonic development GO process connecting these endpoints. Although these conazoles did rank high in these predictive models, this should not be construed as a risk of developmental toxicity, which would involve all elements of hazard and exposure in realworld use scenarios.
Xenobiotic Metabolism
Although the assays allow for limited ability for drug metabolism and this work did not address the bioavailability of the ToxCast chemicals to the embryo in vivo, it does give some indication about chemicals disrupting xenobiotic metabolism, which affects chemical properties. Each species-specific developmental toxicity model utilized CYP assays in a predictive assay set, indicating that xenobiotic metabolism may be playing a pivotal role in developmental toxicity regardless of species. Additionally, from the univariate analyses, rat cleft palate, urogenital, and axial skeletal endpoints associate with the disruption of a range of CYP enzymes, suggesting that these systems may be affected through CYP disruption. Further efforts to characterize chemical properties have not been performed; however, studies are underway to determine how chemical features could augment the ability of the bioassays used in this data set to predict developmental toxicity.
Dosage
According to the ''Principles of Teratology,'' one would assume that the in vivo data follow a trend of FWR to malformations to fetal loss with increasing dose, although a majority of the ToxCast chemicals with ToxRefDB studies do not display this trend. This may be because most guideline studies test three dose levels to ensure that a no observed effect level is identified at the lowest level, whereas effects are usually confined to the high level. Graded responses across the limited multiple dose levels may not be seen. This principle has been a guiding factor for studies linking developmental toxicity with FWR (Kavlock et al., 1995) . However, the predictive model did not uncover a simple relationship between dLEL potency, suggesting that an additional focus on specific endpoints is necessary to inform mechanisms and to incorporate dosage into these models. LEL values for in vivo endpoint observation and AC50 values for in vitro assay calls may play a role in determining these underlying associations.
Predicting Developmental Toxicity
This analysis provides a unique perspective in using HTS assays to predict developmental toxicity potential. First, for this research project, we used the dLEL for defining positive and negative developmental toxicants, rather than lowest observed adverse effect level (LOAEL), which is used in regulatory toxicology. We previously defined dLEL in Knudsen et al. (2009) as meaning that some developmental effect was observed from the ToxRefDB database, whether at the developmental LOAEL or not. Hydroureter is an example of an endpoint from animal toxicity studies with limited toxicological relevance to human health risk. This is considered a transitory and nonspecific disturbance of fetal development whether or not it is treatment related. In children, hydroureter is a common but generally reversible symptom of urinary tract obstruction/infection. Furthermore, hydroureter in children can ascend to pyelonephritis, which is an inflammatory defect of the kidney that can lead to histological damage (and permanent scarring) of renal tissue, causing a range of postnatal functional deficits that are not usually assessed in an animal 124 SIPES ET AL. developmental toxicity study. Our results indicate that the category of ureteric defects can be linked to cleft palate, a toxicologically relevant endpoint, through GO processes common to HTS assays associated with these defects (Fig. 7) . The model included all dLEL endpoints, irrespective of their implications for regulatory toxicology, and we think this is the current best practice for predictive modeling of developmental toxicity based solely on ToxCast and ToxRefDB data. As the developmental toxicity field advances, predictive modeling may focus on more sensitive in vivo endpoints or pathways of concern, but the predictive modeling approach presented herein would still be applicable. Second, our model does not consider concomitant maternal toxicity as an independent variable. ToxRefDB studies look at maternal and fetal responses differently but cannot answer whether fetal effects are primary (direct) or secondary (maternal) to chemical exposure. When we looked at chemicals with dLEL but no mLEL or vice versa, we did not see any predictive value in discriminating between the two. As noted earlier, the Phase I portfolio of ToxCast assays are not specific for molecular pathways and cellular processes that constitute a developmental hazard. Although a battery of in vitro assays that predict chemicals having developmental specificity (dLEL without an mLEL) or sensitivity (dLEL < mLEL) would be significant, this should be construed as a future goal rather than a current limitation. Indeed, a chemical with an effect on an important pathway such as TGFb could disrupt development through direct effects on the embryo (e.g., preventing palatal closure) or through the mother (e.g., uterine vascularity or placental development).
Third, we employ a target-level prediction rather than a response-based prediction. As a predictive screening tool to identify potential developmental toxicants, we recognize nuances that could limit BA, including the somewhat narrow coverage of developmental processes by the Phase I ToxCast assay suite, sensitivity of ToxRefDB endpoints, and considerations of biotransformation. One could anticipate that a single assay focused on morphogenesis and differentiation response such as embryonic stem cells or zebrafish embryos might have a higher BA for smaller numbers of chemicals, e.g., BA around 87% for a more limited set of compounds (Brannen et al., 2010; West et al., 2010) ; however, the chemical targets themselves that initiate a response cannot be deciphered, only pathway-level and endpoint response. The ToxCast model not only includes these endpoints but also adds assays for broader biochemical, molecular, and cellular functions. As such, it provides a global model for target-level inputs on top of response-based outputs. The BA, which is significantly greater than random, thus predicts based on chemical biology across a larger set of endpoints and larger set of chemicals than models with higher BA. Additionally, if we focus our efforts specifically on mode of action, such as, for example, stem cell differentiation or blood vessel development, we get much improved performance (~80-90% BA) Kleinstreuer et al., 2011) . Putting all of these efforts together may ultimately give the best predictive models and mechanisms of action.
Limitations
Care needs to be taken in using these associations and predictions for all applications. Chemical selection included mainly food use pesticides in which we currently have in vivo developmental toxicity studies. ToxCast is currently being expanded to include a broader diversity of chemicals in Phase II, which includes bona fide developmental toxicants (e.g., valproate, retinoic acid, 5-fluorouracil, etc.) and a more diverse chemical landscape. Because the endpoints were characterized from the guideline studies, some chemicals with a dLEL in one species may not have been tested at an equivalent administered dose level in the other species, whereas others may not be comparable due to maternal toxicity at lower dosages. Additionally, the descriptions of the endpoints in these studies are relatively broad in nature and specific endpoints such as microphthalmia that give a subtle visual phenotype may have been missed if the study was not designed to specifically capture endpoints as these. Furthermore, developmental targets and appropriate assays may not have been included in these HTS analyses. These limitations aside, the usefulness of these models is to gain new insight into potential targets for developmental toxicity among the various endpoints. Additionally, one would not assume that all developmental defects are occurring in the same way, and while our analysis gives associated targets over the aggregated endpoint, screening the data on a chemical by chemical basis may be needed to give a better insight into how each chemical may be causing developmental toxicity.
Future Directions
We hope to use predictions from the present model, along with knowledge drawn from the literature, to further HTS and prioritizing the testing of environmental chemicals for developmental toxicity. Additionally, we hope to identify specific embryonic organ systems or biological themes (e.g., limb bud or embryonic vasculature development) for additional predictive models that capture developmental complexities. Focusing on particular embryonic organs or themes will narrow the relevant chemical and biological space, allowing for more detailed analyses. Additionally, in silico agent-based models can be used to integrate and visualize the process of tissue disruption, from genes to cellular processes to tissuelevel perturbations. Pathways and processes that are linked to particular developmental defects can be studied in these various models, and model outputs can be used for hypothesis generation. These models can also be used to identify missing ToxCast HTS assays, representing important developmental toxicity pathways and processes. These additional data would likely improve the performance of future predictive models of developmental toxicity.
